Somatostatin-receptor-negative carcinoid tumour responsible for Cushing's syndrome. 1998

H Takami, and Y Ogino, and K Tanaka, and A Kubo
First Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.

A 30-year-old man presenting with Cushing's syndrome was admitted in 1995. A diagnosis of ectopically ACTH-secreting, primary-unknown abdominal carcinoid tumour was made. The patient's plasma ACTH and cortisol levels failed to decrease after short-term treatment with octreotide, and somatostatin-receptor scintigraphy did not show any accumulation in the tumour. The patient died 1 year after admission. This is a relatively rare somatostatin-receptor-negative case of this disease and it appears necessary to test for the presence of somatostatin receptors before treating with octreotide.

UI MeSH Term Description Entries
D008297 Male Males
D009382 Neoplasms, Unknown Primary Metastases in which the tissue of origin is unknown. Neoplasm Metastasis, Unknown Primary,Neoplasms, Occult Primary,Occult Primary Neoplasms,Unknown Primary Tumors,Unknown Primary Neoplasm Metastasis,Unknown Primary Neoplasms,Neoplasm, Occult Primary,Neoplasm, Unknown Primary,Occult Primary Neoplasm,Primary Neoplasm, Occult,Primary Neoplasm, Unknown,Primary Neoplasms, Occult,Primary Neoplasms, Unknown,Primary Tumor, Unknown,Primary Tumors, Unknown,Tumor, Unknown Primary,Tumors, Unknown Primary,Unknown Primary Neoplasm,Unknown Primary Tumor
D002276 Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182) Argentaffinoma,Carcinoid,Carcinoid, Goblet Cell,Argentaffinomas,Carcinoid Tumors,Carcinoids,Carcinoids, Goblet Cell,Goblet Cell Carcinoid,Goblet Cell Carcinoids,Tumor, Carcinoid,Tumors, Carcinoid
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000008 Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN. Abdominal Neoplasm,Neoplasm, Abdominal,Neoplasms, Abdominal
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D017481 Receptors, Somatostatin Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter. Receptors, Somatotropin Release Inhibiting Hormone,Somatostatin Receptors,Receptors, SRIH,SRIH Receptors,Somatostatin Receptor,Receptor, Somatostatin
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

H Takami, and Y Ogino, and K Tanaka, and A Kubo
April 1995, The Journal of clinical endocrinology and metabolism,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
April 1984, Archives of disease in childhood,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
July 1980, Pathology,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
June 2000, Clinical endocrinology,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
June 2000, Clinical endocrinology,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
January 2011, European journal of dermatology : EJD,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
January 1994, Digestion,
H Takami, and Y Ogino, and K Tanaka, and A Kubo
January 1957, Lancet (London, England),
Copied contents to your clipboard!